Combination therapy in A549 cells

Somatostatin Receptor Based Imaging and Radionuclide Therapy

“…All these studies indicate that the hSSTr2 reporter based imaging is a promising method to track gene delivery and expression. The detailed functions of hSSTr2 reporter gene based imaging are demonstrated below: repetitively observing the magnitude, duration, and time variation of gene expression both in vitro and in vivo [ 30 ], studying the biodistribution of gene transfer vector in mice or patients [ 25 ], optimizing the administration dose of vector encoding hSSTr2 reporter gene and/or other therapeutic genes [ 24 ], predicting treatment response of transfected tumor to PRRT [ 21 ], and monitoring antitumor effects of various treatments including hSSTr2 gene or another therapeutic gene based therapy [ 21 , 99 ].…”

“…Gene therapy vectors containing both hSSTr2 reporter gene and a second therapeutic gene encoding TK or CD have been investigated [ 21 , 99 ]. The hSSTr2 is available not only for noninvasive imaging of the expression of transferred gene, but also for radionuclide therapy [ 21 ]. A synergistic therapeutic effect may be achieved through the combined gene therapy.…”

“…Surgery, chemotherapy, and radiotherapy have limited effects on improving survival for patients diagnosed with these cancers [ 20 ]. Therefore, some studies [ 21 , 22 ] have tried to explore the applications of hSSTr2 reporter gene based imaging and therapy in SSTR negative or weakly positive tumors to provide a new strategy for the management of these tumors. To this end, the target gene hSSTr2 should be inserted into gene transfer vectors to induce transfected tumors to express SSTR2 [ 23 – 25 ] and assure that hSSTr2 expression could occur on tumor cell membranes.…”

“…Tumors transfected with hSSTr2 gene can be monitored by external gamma camera, single photon computed emission tomography (SPECT), or PET imaging techniques with radiolabeled SST analogs [ 29 ]. These in vivo hSSTr2 based imaging methods have several advantages: repetitively observing the expression levels of hSSTr2 or other genes within transfected tumors [ 30 ], studying the biodistribution of gene transfer vectors [ 25 ], predicting the effects of PRRT, and monitoring the time course of tumor growth and the efficacy of antitumor gene therapy [ 21 ]. The hSSTr2 gene transfer not only allows for some SSTR negative tumors to be imaged in vivo , but also can be useful for antitumor radionuclide therapy.…”

“…Furthermore, by the simultaneous inclusion of a second therapeutic gene like thymidine kinase (TK) or cytosine deaminase (CD), it is possible to obtain a dual gene vector that includes hSSTr2 working as a reporter gene for in vivo imaging as well as a therapeutic gene for radionuclide therapy. Preliminary studies suggested that a synergistic therapeutic effect could be achieved following dual gene transfer with one vector encoding both hSSTr2 reporter gene and a second therapeutic gene [ 21 , 34 ].…”